Cytiva携多款创新技术和产品与您相约2024 ASGCT年会-医疗器械网

Cytiva携多款创新技术和产品与您相约2024 ASGCT年会

来源：Cytiva（思拓凡）分类：政策 2024-05-06 10:00:10 61阅读次数

一年一度的全球盛会——第27届美国基因与细胞治疗学会年会 (ASGCT 2024) 将于当地时间2024年5月7日~11日在美国马里兰州巴尔的摩盛大召开。将携多款创新技术和产品重磅参展，欢迎您莅临现场参观交流，精彩活动，敬请期待。

展位号 # 1717

（“要去要去” 谐音好记）

精彩报告推荐

上下滑动阅读更多内容

话题1：The future of viral vector manufacturing: Is it time for cell lines to take center stage?

时间：5月9日周四中午12:15–1:15pm，Room 327-329

演讲者：Clive Glover ()，Sybil Danby ()

圆桌讨论：

Barry Byrne (Powell Gene Therapy Center at the University of Florida)
Kimberly Benton (Dark Horse Consulting)
Markus Haindl (Roche Diagnostics)
Nicole Paulk (Siren Biotechnology)

话题2：Ex vivo engineering of T cells and hematopoietic stem cells using RNA-lipid nanoparticles for cell and gene therapies

时间：5月9日周四下午4:45-5:15pm, Room 337-338

演讲者：Dr. Angela Zhang, Product Management Leader ()

话题3：Generation of a stable high-titer production cell line for therapeutic AAV vectors

时间：5月10日周五下午5:15-5:30pm, Ballroom 3 (Abstract #295)

演讲者：Stefan Seeber (Roche)

话题4：Comparative Analysis of Sterile Grade Filters in Adeno-Associated Virus (AAV) Manufacturing: Accelerating First-in-Human AAV Therapeutic Production with Quality by Design Principles

时间：5月8日周三下午3:00-3:15pm | Ballroom 3 (Abstract #66)

演讲者：Angela N. Johnson, PHD, MSE, RAC ()

话题5：Systematic analysis of primary field data from biologics therapy regulatory non-approvals: Why aren’t we talking about FDA rejections?

时间：5月8日周三下午5:10-5:27pm | Rooms 314-317 (Abstract #128)

演讲者：Limin Wang, Lead Regulatory Strategist ()

创新技术产品

NanoAssembler Spark系统

NanoAssembler Ignite系统

ELEVECTA细胞系

*Transient即将上市，若您对现场展示的产品或解决方案感兴趣，可与技术专家现场交流。

海报摘要推荐

上下滑动阅读更多内容

Abstract编号#531：Membrane Chromatography for Preparation of AAV at the Manufacturing Scale

[Wednesday Posters: AAV Vectors -Product Development Manufacturing and Approval Considerations]

Abstract编号#559：ELEVECTA Transient Cell Line: Enabling rAAV Production with Low-Level hcDNA Encapsidation

[Wednesday Posters: AAV Vectors - Product Development Manufacturing and Approval Considerations]

Abstract编号#1053：Evaluation of Cell Growth and AAV Production in a Fixed-Bed Bioreactor to Streamline Process Development

[Thursday Posters: AAV Vectors - Product Development Manufacturing and Approval Considerations]

Abstract编号#1159：Comparative Interrater Analysis of Regulatory Challenges in Recently Approves Gene Therapies for Sickle Cell Disease: Towards a Semi-Quantitative Method for Assessing Gene Therapy Regulatory Development Complexity

[Thursday Posters: Genetic Disorders of the Blood and Immune System]

Abstract编号#1190：Optimization of Multiplex CRISPR-Cas9 Editing of Human Primary T Cells Using Lipid Nanoparticles (LNP’s) and Subsequent Off-Target Evaluation

[Thursday Posters: Gene Disruption and Excision]

Abstract编号#1245：Efficient Gene Editing in CD34+ Hematopoietic Stem and Progenitor Cells Using Non-Viral Lipid Nanoparticles

[Thursday Posters: Other Nonviral Delivery]

Abstract编号#1258：Strategies for Producing Clinical and Commercial RNA-LNP Drug Products

[Thursday Posters: Other Nonviral Delivery]

Abstract编号#1720：Effect of LNP Components on mRNA Mediated Protein Expression of Lipid Nanoparticles in Different Organs

[Friday Posters: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates]

Abstract编号#1748：Gene Editing in Liver Towards the Treatment of Life-Threatening Cardiovascular Diseases: POC for Efficient In-Vivo Genome Editing/Base Editing Using Lipid Nanoparticle Library

[Friday Posters: Other Nonviral Delivery]

Abstract编号#1818：Development and Evaluation of Immuno-Cell Growth Medium (Akron ICGM?): A Novel Xeno-Free Cell Expansion Medium Demonstrated to Support Superior Cell Activation, Viability, Transduction and Expansion

[Friday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies]

Abstract编号#1845：Navigating Pitfalls in the Adenovirus Development: From Drug Discovery to Clinics and Beyond

[Friday Posters: Vector Product Engineering, Development, and Manufacturing]

基因药物如基于病毒载体的基因疗法和RNA脂质纳米颗粒 (RNA-LNP) 等正在开拓新的领域。尽管新疗法已经取得了一定的进展，但这些技术的发展潜力几乎是无限的。当您对科学进行创新时，也从未止步，始终致力于让您比以往更快、更高效、更节省成本的发现、开发并推进商业化进程。无论您使用何种基因递送方式，都会为您提供合适的解决方案。